ICU Medical, Inc.
NASDAQ:ICUIMedical - Instruments & Supplies
+$0.89 today
- Market cap
- $4.46B
- Beta
- 0.78
- P/E (TTM)
- 74.2
- EPS (TTM)
- $1.87
Volume 0.21M
Average 0.29M
ICUI Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
ICU Medical, Inc.NASDAQ: ICUI
Gross Margin · Q2 FY2026 · quarter ended Jun 2026
Gross margin widens to 42.6%
Gross margin was 42.6% in Q2 FY2026, up 4.7 pp from a year earlier. On a trailing-twelve-month basis it was 37.6%, up 1.7 pp year over year. Over 3 fiscal years it widened by 6.2 pp.
Context
- Gross margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 36.8%
- Year-over-year change
- +2.1pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 36.8% | +2.1pp |
| FY2024 | 2024-12-31 | 34.6% | +1.9pp |
| FY2023 | 2023-12-31 | 32.8% | +2.1pp |
| FY2022 | 2022-12-31 | 30.6% | -6.7pp |
| FY2021 | 2021-12-31 | 37.3% | — |
Gross Margin vs competitors
How ICUI compares with its peers on the latest reported figures
- ICUI's LTM Jun 2026 gross margin of 37.6% is the 4th highest of the 5 companies compared; the peer median is 50.4%.
- Its year-over-year change of +1.7 pp is the highest of 5, against a peer median of -1.9 pp.
- Over three fiscal years its change of +6.2 pp compares with a peer median of +3.3 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 61.5% | -2.0 pp | +7.2 pp | |
| LTM Jun 2026 | 53.8% | -1.8 pp | +1.4 pp | |
| LTM Sep 2026 | 47.0% | +1.6 pp | +5.2 pp | |
| LTM Jun 2026 | 37.6% | +1.7 pp | +6.2 pp | |
| LTM Jun 2026 | 30.1% | -5.2 pp | -5.2 pp | |
| Peer median (excluding ICUI) | 50.4% | -1.9 pp | +3.3 pp | |
Competitors are the stored peer set for ICUI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.32B | 2.28B | 2.26B | 2.38B | 2.23B |
| Cost of Revenue | 824.82M | 1.58B | 1.52B | 1.56B | 1.41B |
| Gross Profit | 491.49M | 697.76M | 739.87M | 824.78M | 819.66M |
| Gross Margin | 37.3% | 30.6% | 32.8% | 34.6% | 36.8% |
| Research & Development | 47.5M | 92.98M | 85.34M | 88.62M | 87.5M |
| Selling, General & Admin | 302.58M | 608.35M | 606.69M | 638.76M | 625.21M |
| Operating Expenses | 368.25M | 740.66M | 717.05M | 781.82M | 712.71M |
| Depreciation & Amortization | 89.7M | 235.15M | 228.77M | 219.51M | 200.74M |
| EBITDA | 213.86M | 191.55M | 253.2M | 260.04M | 309.29M |
| EBITDA Margin | 16.2% | 8.4% | 11.2% | 10.9% | 13.9% |
| Operating Income | 123.25M | (42.9M) | 22.83M | 42.96M | 106.95M |
| Operating Margin | 9.4% | -1.9% | 1.0% | 1.8% | 4.8% |
| Interest Income | 2.84M | 4.43M | 7.51M | 10.79M | 10.31M |
| Interest Expense | 858K | 70.81M | 102.73M | 106.54M | 105.38M |
| Other Income / Expenses | (59K) | (71.51M) | (101.12M) | (108.98M) | (103.78M) |
| Income Before Tax | 123.19M | (114.41M) | (78.3M) | (66.01M) | 3.17M |
| Pre-Tax Margin | 9.4% | -5.0% | -3.5% | -2.8% | 0.1% |
| Income Tax Expense | 20.05M | (40.12M) | (48.64M) | 51.68M | 2.44M |
| Net Income | 103.14M | (74.29M) | (29.66M) | (117.69M) | 732K |
| Net Margin | 7.8% | -3.3% | -1.3% | -4.9% | 0.0% |
| EPS (Basic) | 4.86 | (3.11) | (1.23) | (4.83) | 0.03 |
| EPS (Diluted) | 4.74 | (3.11) | (1.23) | (4.83) | 0.03 |
| Weighted Avg Shares | 21.21M | 23.87M | 24.09M | 24.39M | 24.64M |
| Weighted Avg Shares (Diluted) | 21.78M | 23.87M | 24.09M | 24.39M | 24.9M |
ICU Medical, Inc.
NASDAQ:ICUI
Intrinsic Alpha fair value
Locked
Current Price
$178.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.